The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: 0.00 (0.00%)
Spread: 0.30 (9.677%)
Open: 3.25
High: 3.25
Low: 3.10
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: US Stocks Seen Mixed As Tech Giants Report

Tue, 21st Jul 2015 11:08

LONDON (Alliance News) - UK stocks are higher midday Tuesday as sentiment is being driven by company news and the movement in gold prices, while Wall Street is called for a mixed open ahead of the release of results from several US technology giants.

The FTSE 100 is up 0.2% at 6,798.97 points, the FTSE 250 is up 0.2% at 17,816.81, and the AIM All-Share is up 0.1% at 759.10. European major indices also are higher, with the CAC 40 in Paris up 0.2%, and the DAX 30 in Frankfurt up 0.1%.

US futures point to a mixed open, with the DJIA pointed down 0.1%, the S&P 500 flat, and the Nasdaq 100 up 0.2%. The Nasdaq Composite reached Monday a new record closing high at 5,218.85 points.

US technology stocks Apple, Microsoft or Yahoo are set to report results on Tuesday after the US market close, following IBM, which reported results Monday after the market close.

IBM said that its second quarter profit fell 17% from last year, as revenue declined 13.5%. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. At the same time, IBM maintained its full year operating earnings outlook. The company now expects a modest increase in free cash flow, improved from its prior expectation of flat.

Gold is slightly higher on the day Tuesday at USD1,106.41 per ounce. The price of gold has recovered after slumping Monday morning to USD1,073.40 an ounce, a level it hasn't seen since early 2010. The precious metal traded at USD1,144.17 an ounce on Friday before its recent sell-off.

The decline in the gold has come amid speculation that the Federal Reserve will hike US interest rates as soon as September. Fed Chair Janet Yellen told Congress last week that the economy is improving at a pace that should allow the US central bank to begin normalizing rates by the year's end.

Kit Juckes, analyst at Societe Generale, says,"September and December Fed Funds futures are moving higher (in rate terms), with a third-quarter (ie, Sept) hike seen now as a distinct possibility again, and a fourth quarter hike as a strong probability."

The US dollar strengthened against most major currencies on Tuesday morning, in response to comments by St. Louis Federal Reserve President James Bullard that there is more than a 50% chance for a Fed rate hike in September.

"I see September having a 50% probability right now" for a boost in the Fed's overnight short-term interest rate target, Bullard told Fox Business Network. "The economy is much closer to normal today than it's been in quite a while, certainly over the last five years," he added.

The pound has recovered some of the ground gained by the dollar and is now flat at USD1.5555.

London-listed miners were hit Monday by the slump in gold prices. On Tuesday, the stocks are rebounding, with Fresnillo up 3.3%, Randgold Resources up 2.1%, Antofagasta up 0.9%, and BHP Billiton up 0.7%. In the FTSE 250, KAZ Minerals is up 2.7% and Acacia Mining is up 1.9%.

Outside miners, general insurers Admiral Group, up 3.5%, and RSA Insurance Group, up 1.5%, are higher after roadside assistance company AA found that car and home insurance premiums are set to rise due to an upcoming increase in the UK's insurance premium tax. AA said it thinks premiums may rise due to the decision by the UK government to increase the standard rate of insurance premium tax to 9.5% from 6%.

AO World is the biggest gainer in the FTSE 250, up 9.7%, after it said it is on track with its long-term strategic process as it continues to build brand awareness and plans to expand its services in Europe.

The online domestic appliances retailer said that sales continue to "build satisfactorily" in Germany, where it has entered into a ten-year lease for a new European distribution facility in Bergheim near Cologne, expecting to take occupation during the first half of the financial year 2017. The property will replace two of its existing sites and will facilitate expansion into countries surrounding Germany, the company said.

In the UK, AO World said revenue grew 6.5% in the three months to June 30, with orders up 13.9%, while AO.com experienced revenue growth of 11.2%. It said it had a strong start to trading in July and is encouraged by the indications of growth in housing transactions and disposable income in the broader market.

In the AIM All-Share index, ValiRx is up 23% after the life sciences company provided a positive update on the ongoing phase I/II dose escalation clinical trial of its cancer drug VAL201. The company said that over the last month the trial has continued to demonstrate safety and tolerability and no significant adverse effects have been recorded. The next dose escalation has been approved as a result of safety and tolerability data, which ValiRx said "may prove sufficient to show anti-tumour activity."

Meanwhile, Versarien is up 12%. The advanced engineering materials company posted a widened pretax loss for its recently ended financial year as higher costs offset strong growth in revenue, but expressed optimism for its current year. The company reported a pretax loss of GBP866,000 for the year to end-March, widened from a pretax loss of GBP653,000 a year before, as a rise in revenue to GBP5.0 million from GBP3.0 million was offset by a rise in operating expenses and exceptional costs of GBP307,000.

Nasstar is down 13%. The cloud computing services company said that while its first half trading in 2015 was in line with its expectations, it now expects to miss its forecasts for the full year due to a series of challenges set to hit the business in the second half. Among those challenges, a key client is consolidated its IT services in the second half and the group is set to lose licensing revenue from another client.

In economic news, UK public sector net borrowing decreased in June from last year, the Office for National Statistics said. Excluding public sector banks, PSNB dropped GBP0.8 billion to GBP9.4 billion in June. It was equivalent to 0.5% of gross domestic product. The decline in net borrowing was resulted from an increase of GBP0.1 billion in central government net borrowing being more than offset by a decrease of GBP1 billion in local government net borrowing.

Still in a very light economic calendar Tuesday is the US Redbook index, due at 1355 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
9 Jan 2019 14:57

ValiRx gives NHS Long Term Plan its seal of approval

(Sharecast News) - Clinical stage biotechnology company ValiRx endorsed the Government's new NHS Long Term Plan to improve the quality of patient care and health outcomes on Wednesday.

Read more
9 Jan 2019 11:25

ValiRx Backs New Long-Term UK Government Plan For NHS

LONDON (Alliance News) - Biotechnology firm ValiRx PLC on Wednesday said it endorses the UK government's new NHS long-term plan."The government's recently announced ten-year a

Read more
18 Dec 2018 15:53

VAL401 results accepted for journal publication, says ValiRx

(Sharecast News) - Clinical stage biotechnology company ValiRx announced the acceptance for publication of the first article containing results from the VAL401 clinical trial by the European Journal of Drug Metabolism and Pharmacokinetics on Tuesday.

Read more
10 Dec 2018 11:07

ValiRx releases positive data from recent VAL201 testing

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Monday that independent analysis of VAL201 data showed a "statistically significant" dose dependant response in the reduction of PSA correlated to time on the Phase l/ll clinical trial, involving patients with hormone-sensitive and hormone-resistant prostate cancer.

Read more
10 Dec 2018 10:59

WINNERS & LOSERS SUMMARY: Just Group Jumps 23% On Regulatory Decision

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------NMC up The

Read more
10 Dec 2018 09:06

ValiRx Reports Positive VAL201 Effect On Patients With Prostate Cancer

LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.The up

Read more
17 Oct 2018 08:36

ValiRx enters finals stages of clinical trials on VAL201

(Sharecast News) - Clinical stage biotechnology company ValiRx's leading anti-cancer therapeutic has entered the concluding stages of its Phase l/ll clinical trial at University College London Hospital.

Read more
25 Sep 2018 13:23

ValiRx Half Year Loss Widens On Expenses And Share Option Charge

LONDON (Alliance News) - Life science company ValiRx PLC on Tuesday reported a widened loss in the first half of 2018 due to expenses and a sizeable share option charge.The company's to

Read more
6 Sep 2018 11:38

ValiRx Says Clinical Study For Lung Cancer Drug VAL401 Is Approved

LONDON (Alliance News) - Clinical stage biotechnology company ValiRx PLC said Thursday its clinical study report on lung cancer drug VAL401 has been signed and approved by principal in ValiRx were

Read more
6 Sep 2018 09:05

ValiRx enters 'very exciting' phase for cancer therapies

(Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.

Read more
14 Jun 2018 11:00

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.6%. The jet engine maker said it will cut

Read more
11 May 2018 16:43

Nicholas Slater Increases ValiRx Stake To 4.5% From 2.7% (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday Nicholas Slater had almost doubled his stake in life science company, which focuses on cancer treatments, to 4.5% after a transaction on raised his

Read more
4 May 2018 17:08

ValiRx Raises GBP950,000 Through Placing To Progress Pipeline (ALLISS)

LONDON (Alliance News) - ValiRx PLC said Friday it has raised GBP950,000 through the issue of 47.5 million shares at 2.00 pence per share.The clinical stage biotechnology company's down

Read more
25 Apr 2018 13:41

"Major" Milestone As ValiRx's VAL201 Is Granted Patent In EU

LONDON (Alliance News) - Biotechnology company ValiRx PLC said Wednesday its VAL201 compound has been granted a patent in the EU.This, it said, follows a US patent which was granted for a a

Read more
19 Apr 2018 12:41

ValiRx Posts Positive Results From VAL101 Compound Pre-Clinical Trials

LONDON (Alliance News) - ValiRx PLC on Thursday said pre-clinical studies showed that its VAL101 compund has a potential to prevent cancer growth at cellular biochemical and genomic molecule is is

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.